Oculogica
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $600k | Seed | |
$1.7m | Early VC | ||
* | N/A | Angel | |
$553k | Grant | ||
N/A | $5.0m | Angel | |
$8.2m | Series A | ||
N/A | $2.0m | Grant | |
* | N/A | $2.0m | Debt |
* | N/A | $2.0m Valuation: $25.0m | Early VC |
* | N/A | $7.6m Valuation: $41.0m | Early VC |
Total Funding | €25.2m |
Related Content
Recent News about Oculogica
EditOculogica is a pioneering medical device company specializing in concussion diagnosis through advanced eye-tracking technology. The company's flagship product, EyeBOX, is the first FDA-cleared concussion assessment tool that does not require a baseline test, making it a significant breakthrough in the field. Oculogica serves a diverse range of clients, including sports organizations, healthcare providers, and medical professionals, addressing the critical need for objective and accurate concussion diagnostics. Operating in the medical technology market, Oculogica's business model revolves around the sale and distribution of its diagnostic devices, along with providing ongoing technical support and regulatory compliance services. Revenue is generated through direct sales, partnerships, and potentially through licensing agreements. The company's commitment to high standards and continuous improvement ensures that it meets the regulatory requirements and customer expectations effectively.
Keywords: concussion diagnosis, eye-tracking technology, FDA-cleared, medical device, healthcare, sports medicine, objective measures, regulatory compliance, technical support, innovation.